Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Salix acquired worldwide rights to Olon's IP relating to amorphous rifaximin. The IP includes a pending
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury